［14］ Muller M, Meijer C, Zaman GJR. et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione s-conjugate transport［J］. Proc Natl Acad Sci USA, 1994, 91:13033-13037.
［15］ Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance［J］. Hematol Oncol North Am, 1995, 9:363-382.
［16］ Klopman G, Shi LM, Ramu A. Quantitative structure-activity relationship of multidrug resistance reversal agents［J］. Mol Pharmacol, 1997, 52:323-334.
［17］ Sikic BI. Modulation of multidrug resistance: at the threshold［J］. J Clin Oncol, 1993, 11:1629-1635.
［18］ Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy［J］. J Clin Oncol, 1995, 13: 1985-1994.
［19］ Wilson WH, Bates S, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy［J］. J Clin Oncol, 1995, 13:1995-2004.
